📣 Second Pre-Clinical Study on Symetrian™ Published

Unigen Director of Pre-Clinical Development Elected to IASC Board

Tacoma, WA – June 10, 2022 – Unigen Inc. has announced that Dr. Mesfin Yimam, DVM, MS has been elected for a 3-year term to the International Aloe Science Council (IASC) Board of Directors. Dr. Yimam brings to the IASC nearly 2 decades of experience working on research projects directly related to the Aloe industry. As Unigen’s Director of Pre-Clinical Development, Dr. Yimam’s research is primarily focused on discovering natural products based on novel dietary ingredients for osteoarthritis, metabolic disorders, sleep, brain health, and immunity.

“Aloe is such a magical plant that shows unexpected health benefits beyond historic usage in skin care and general well-being,” said Dr. Yimam, “most notably enhancing insulin sensitivity and maintaining immune homeostasis”. “I hope to bring experience and knowledge of my past 16 years of research of Aloe to IASC and to translate the Aloe scientific results through IASC to expand the awareness and usage of Aloe in global consumer markets.”

Dr. Yimam is a board-certified Doctor of Veterinary Medicine and received his doctorate in veterinary medicine from Addis Ababa University, Ethiopia. Currently managing the pre-clinical development team at Unigen, he has contributed to multiple projects in developing and validating several in vivo disease models; the optimization of in vivo experiments to support safety, efficacy, mechanism of actions, and pharmacokinetics studies, ensuring research strategy and procedures in compliance with regulations and organization guidelines under FDA and other regulatory agencies.

In addition to publishing multiple peer-reviewed articles, Dr. Yimam has also co-invented several issued and pending patents, presented his work in a range of scientific conferences, and is an invited reviewer for reputable journals for scientific publications.

“Dr. Yimam is well qualified director for an industry science focused association like IASC,” said Dr. Qi Jia, PhD, Unigen’s CEO. “Dr. Yimam will bring in unique knowledge and experience in his aloe research to IASC that will enrich the scientific representatives of the organization and lead to more research especially human clinical trials using materials derived from Aloe plants.”

Visit Unigen at SupplySide West – Booth #3472 November 2-3, 2022 (www.west.supplysideshow.com)

About Unigen

Unigen discovers, develops, and manufactures proprietary natural-product active ingredients for dietary supplements,cosmetic and personal care products, prescription medical food, and botanical drug products. The Company discovers its ingredients through its high throughput screening PhytoLogix® platform applied to a proprietary well-annotated collection of botanicals and a legacy mining approach applied to botanicals having known medicinal benefits. The mechanism of action, safety, and efficacy is documented with extensive pre-clinical in vitro and in vivo testing and human clinical studies. Unigen protects its discoveries with issued patents and patent filings in all major territories and manufactures its products to GMP standards. Unigen commercializes its proprietary ingredients through licensing and ingredient supply alliances with commercial partners engaged in the manufacturing, distributing, and marketing of endproducts in each of Unigen’s target markets.

Kathy Markham, Marketing Manager
Email: kmarkham@unigen.net